United States

Celgene Corp (CELG.O)

CELG.O on Nasdaq

23 May 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

Celgene reports 8.1 pct passive stake in Oncomed Pharmaceuticals
Wednesday, 24 Aug 2016 06:23am EDT 

Oncomed Pharmaceuticals :Celgene Corporation reports 8.1 pct passive stake in Oncomed Pharmaceuticals Inc as of August 23, 2016 - SEC filing.  Full Article

Celgene reports Q2 GAAP earnings per share $0.75
Thursday, 28 Jul 2016 07:30am EDT 

Celgene Corp : Celgene reports second quarter 2016 operating and financial results . Q2 adjusted earnings per share $1.44 . Q2 revenue $2.754 billion versus I/B/E/S view $2.7 billion . Q2 GAAP earnings per share $0.75 . Q2 earnings per share view $1.38 -- Thomson Reuters I/B/E/S . Abraxane sales for Q2 were $249 million, a 2 percent increase year-over-year . Sees 2016 adjusted diluted EPS $5.70 to $5.75 . Sees 2016 revlimid net sales about $6.8 billion . FY2016 earnings per share view $5.70, revenue view $11.01 billion -- Thomson Reuters I/B/E/S . 2016 net product sales guidance for Pomalyst/Imnovid, Abraxane and Otezla remain unchanged . 2016 guidance updated: revlimid and total net product sales; EPS . Sees 2016 adjusted operating margin approximately 54.0% . Sees 2016 GAAP diluted eps $3.82 to $4.05 .Sees 2016 total net product sales about $11 billion.  Full Article

Celgene and LYSARC provide update on the phase III study
Monday, 25 Jul 2016 04:30pm EDT 

Celgene Corp : Interim analysis of overall survival, a key secondary endpoint, showed no benefit in revlimid . Based upon these interim results, Celgene does not currently plan to seek approval for this indication . Says is also exploring multiple clinical candidates in non-hodgkin lymphomas and T-cell lymphomas . Celgene and LYSARC provide update on the phase III 'remarc' study of revlimid maintenance treatment in patients with diffuse large B-cell lymphoma responding to first-line R-chop therapy .Remarc achieved primary endpoint of a statistically significant improvement in progression-free survival for patients receiving revlimid.  Full Article

BRIEF-Jounce Therapeutics to collaborate with Celgene to develop immuno-oncology therapies
Tuesday, 19 Jul 2016 07:00am EDT 

Adds dropped words in second and third bullets.Jounce Therapeutics: Jounce Therapeutics says to receive upfront payment of $225 million and $36 million equity investment, up to $2.3 billion in future milestone payments . Jounce Therapeutics announces global strategic collaboration with Celgene to develop, commercialize immuno-oncology treatments for cancer patients . Jounce Therapeutics says Celgene to get options to jointly develop JTX-2011, additional immunotherapies targeting B cells, T regulatory cells .Celgene has option to opt-in at defined stages of development across programs; after opt-in, cos to share u.s. Profits, losses.  Full Article

Celgene International says European Commission approved Revlimid
Friday, 15 Jul 2016 02:06am EDT 

Celgene International Sarl :European Commission approved Revlimid for treatment of adult patients with relapsed or refractory mantle cell lymphoma.  Full Article

Celgene announces additional $3 bln share repurchase authorization
Wednesday, 15 Jun 2016 07:30am EDT 

Celgene Corp : Celgene announces additional $3 billion share repurchase authorization .Now has a total of approximately $5.3 billion available from previous authorizations plus new authorization.  Full Article

Bionor Pharma says possible extension of alliance with Celgene
Monday, 13 Jun 2016 10:07am EDT 

Bionor Pharma ASA :Says scientific collaborations include possible extension of ongoing collaboration with Celgene Corporation Full Article

Acceleron, Celgene says data with Luspatercept show increases in hemoglobin levels
Friday, 10 Jun 2016 07:00am EDT 

Acceleron Pharma Inc : Acceleron and Celgene announce updated results from an ongoing Phase 2 study of Luspatercept in beta-thalassemia presented at the 21st congress of the European Hematology Association . Longer term data with investigational drug Luspatercept show sustained increases in hemoglobin levels, reduced transfusion burden . Results showed 51% of patients with lower risk MDS treated with Luspatercept (n=49) achieved increased hemoglobin levels .Results showed 36% of patients achieved a hemoglobin increase of at least 1.5 g/dl in Luspatercept 3-month base study.  Full Article

Mylan launches generic vidaza injection
Thursday, 2 Jun 2016 07:52am EDT 

Mylan NV : Mylan launches generic vidaza injection .Mylan NV says U.S. Launch of azacitidine for injection, 100 mg/vial, which is a generic version of Celgene's vidaza injection, 100 mg/vial.  Full Article

TriNetX enters into collaboration with celgene to advance clinical trial design and research for next-generation medicines
Tuesday, 24 May 2016 01:00pm EDT 

TriNetX :Announced collaboration with celgene corp to advance clinical trial design and research for celgene's next-generation therapeutic programs.  Full Article

More From Around the Web

Celgene MS drug clears key trial, but disability data falls short

Celgene Corp's multiple sclerosis drug met the main goal of reducing annualized relapse rate, compared with Biogen Inc's Avonex, in a second late-stage trial, but failed to outperform Avonex in slowing disability progression rate.